Annovis Bio is a clinical stage, drug platform company addressing neurodegeneration, such as Alzheimer's disease (AD) and Parkinson's disease (PD). Co.'s pipeline consists of: its primary product candidate, Buntanetap, which is an orally administered drug being developed for chronic indications such as AD and PD; ANVS405, which is an intravenous drug being developed for acute indications, and is focused on protecting the brain after TBI and/or stroke; as well as ANVS301, which is an orally administered drug being developed to increase cognitive capability in later stages of AD and dementia. The ANVS stock yearly return is shown above.
The yearly return on the ANVS stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2023 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the ANVS annual return calculation with any dividends reinvested as applicable (on ex-dates).
|